(Q53001093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

acute myeloid leukemia

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jakob R. Passweg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

J J Cornelissen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J Versluis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

W L J van Putten

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J Maertens

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

H B Beverloo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

P J M Valk

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M van Marwijk Kooy

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

P W Wijermans

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M R Schaafsma

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

B J Biemond

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M-C Vekemans

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

D A Breems

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

L F Verdonck

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M F Fey

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M Jongen-Lavrencic

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J J W M Janssen

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

G Huls

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J Kuball

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

T Pabst

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

C Graux

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

H C Schouten

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Gratwohl

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

E Vellenga

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

G Ossenkoppele

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

B Löwenberg

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

HOVON

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

SAKK Leukemia Groups

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

27 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1041-1050

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.332

23 February 2020

exact match

0 references

cites work

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Therapeutic advances in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Acute myeloid leukaemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

The evolving molecular genetic landscape in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

The myth of the second remission of acute leukemia in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Renaissance of autologous stem cell transplantation for AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Graft-versus-disease effect following allogeneic transplantation for acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

Long-term results of the MRC AML10 trial.

21 January 2018

1 reference

12 December 2020

Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (H

1 reference

12 December 2020

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.

1 reference

12 December 2020

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

12 December 2020

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

1 reference

12 December 2020

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A

1 reference

12 December 2020

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

1 reference

12 December 2020

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

1 reference

12 December 2020

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission

1 reference

12 December 2020

Analysis of survival by tumor response.

1 reference

12 December 2020

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia

1 reference

12 December 2020

Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience

1 reference

12 December 2020

WTAP is a novel oncogenic protein in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.332

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/LEU.2014.332

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428261%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference